Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg

ApprovedTerminated
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Interstitial Cystitis

Conditions

Interstitial Cystitis

Trial Timeline

Sep 1, 2003 → Jun 1, 2011

About Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg

Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg is a approved stage product being developed by Johnson & Johnson for Interstitial Cystitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00086684. Target conditions include Interstitial Cystitis.

What happened to similar drugs?

0 of 4 similar drugs in Interstitial Cystitis were approved

Approved (0) Terminated (1) Active (3)

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00086684ApprovedTerminated

Competing Products

20 competing products in Interstitial Cystitis

See all competitors
ProductCompanyStageHype Score
Ferumoxytol + GadobutrolLipella PharmaceuticalsPhase 1
19
LP-08 80mg + Normal saline + LP-08 20mgLipella PharmaceuticalsPhase 2
25
tacrolimusAstellas PharmaPre-clinical
26
ASP3652 + PlaceboAstellas PharmaPhase 2
35
Mirabegron + PlaceboAstellas PharmaPhase 3
32
TacrolimusAstellas PharmaPhase 2/3
38
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
42
Placebo + JNJ-42160443Johnson & JohnsonPhase 2
27
BOTOX + Placebo for BOTOXAbbViePhase 2
35
NS-863 Low Dose + NS-863 High DoseNippon ShinyakuPhase 2
42
INS316 solution for inhalation + hypertonic saline 3% sodium chloride solutionMerckPhase 2
27
Abituzumab 1500 mg + Abituzumab 500 mg + PlaceboMerckPhase 2
27
MK-2225 + PlaceboMerckPhase 1
21
Certican® + Neoral + Myfortic + Simulect® + CorticosteroidsNovartisPhase 3
40
Pirfenidone + PlaceboRochePhase 2
35
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685PfizerPhase 2
35
Tanezumab + Tanezumab + Tanezumab + TanezumabPfizerPhase 2
27
ERB-041PfizerPre-clinical
18
PF-04383119 + PlaceboPfizerPhase 2
35
AbataceptBristol Myers SquibbPhase 2
42